Alnylam Pharmaceuticals, Inc. (ALNY)

Ticker ALNY · SEC CIK 1178670 · Latest fiscal year ended Dec 31, 2025

Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B for the fiscal year ended Dec 31, 2025, up 65.2% from $2.25B the year before. Net income was $313.75M, a net margin of 8.4% (prior year: −$278.16M). At the end of that fiscal year the company reported total assets of $4.97B and shareholders' equity of $789.18M.

Revenue

$3.71B

+65.2% vs prior year

Net income

$313.75M

Net margin 8.4%

Diluted EPS

$2.33

USD per share

Total assets

$4.97B

At Dec 31, 2025

Equity

$789.18M

At Dec 31, 2025

Shares outstanding

134M

As of Oct 23, 2026

Alnylam Pharmaceuticals, Inc. annual revenue, USD. Hover a bar for the exact figure.

Explore Alnylam Pharmaceuticals, Inc.'s filings

Revenue by year — annual and quarterly revenue with growth rates
Income statement & cash flow — profit, margins, EPS and operating cash flow
Balance sheet — assets, liabilities, equity, cash and debt
SEC filings — 10-K and 10-Q filings with links to EDGAR

Latest SEC filings

Source: SEC EDGAR XBRL company facts for CIK 1178670 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.